Synthesis and isozyme selectivity of small molecule protein kinase C inhibitors: a review of patents

Bibliography

• MANNING G, WHYTE DB, MARTINEZ R, HUNTER T, SUDARSANAM S: The protein kinase complement of the human genome. Science (2002) 298:1912–1934
   PubMed Web of Science ®Google Scholar
• NISHIZUKA Y: Discovery and prospect of protein kinase C research: epilogue. Biochem. (2003) 133:155–158.
   Google Scholar
• MELLOR H, PARKER PJ: The extended protein kinase C superfamily. Biochem. (1998) 332:281–292.
   Google Scholar
• RYKX A, DE KIMPE L, MIKHALAP S et al.: Protein kinase D: a family affair. FEBS Lett. (2003) 546:81–86.
   PubMedGoogle Scholar
• NEWTON AC: Protein kinase C, structure, function and regulation. J. Biol Chem. (1995) 270:28495–28498.
   PubMed Web of Science ®Google Scholar
• NISHIZUKA Y: Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science (1992) 258:607–614.
   PubMed Web of Science ®Google Scholar
• KOLCH W, HEIDECKER G, KOCHS G et al.: Protein kinase Ca-activates RAF1 by direct phosphorylation. Nature (1993) 364:249–252.
   PubMed Web of Science ®Google Scholar
• UEDA Y, HIRAI S, OSADA S et al.: Protein kinase Ca activates the MERK-ERK pathway in a manner independent of Ras and dependent on Raf. J. Biol. Chem. (1996) 271:23512–23519.
   PubMed Web of Science ®Google Scholar
• CAI H, SMOLA U, WIXLER V et ell.: Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Md. Cell. Biol. (1997) 17:732–741.
   Google Scholar
• MARSHALL CJ: Cell signaling; Raf gets ittogether. Nature (1996) 383:127–128.
   PubMed Web of Science ®Google Scholar
• GOODE N, HUGHES K: WOODGETT JR, PARKER PJ: Differential regulation of glycogen synthase kinase-3a by protein kinase C isotypes. J . Biol Chem. (1992) 267:16878–16882.
   PubMed Web of Science ®Google Scholar
• WERLEN G, JACINTO E, XIA Y, KARIN M: Calcineurin preferentially synergises with PKCc to activate JNK and IL-2 promoter in T-lymphocytes. EMBO J. (1998) 17:3101–3111.
   PubMed Web of Science ®Google Scholar
• DORN GW, MOCHLY-ROSEN D: Intracellular transport mechanisms of signal transducers. Ann. Rev. Physiol. (2002) 64:407–429.
   PubMed Web of Science ®Google Scholar
• MOCHLY-ROSEN D: Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science (1995) 268:247–251.
   PubMed Web of Science ®Google Scholar
• MASUR K, LANG K, NIGGEMANN B, ZANKER KS, ENTSCHLADEN F: High PKCa and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. MoL Biol. Cell (2001) 12:1973–1982.
   PubMed Web of Science ®Google Scholar
• ENGERS R, MRZYK S, SPRINGER E et al.: Protein kinase C in human renal cell carcinomas: role in invasion and differential isoenzyme expression. Br. J. Cancer (2000) 82:1063–1069.
   PubMed Web of Science ®Google Scholar
• PARSONS M, KEPPLER MD, KLINE A et al.: Site-directed perturbation of protein kinase C-integrin interaction blocks carcinoma cell chemotaxis. Mol Biol. Cell (2002) 22:5897–5911.
   Google Scholar
• PODAR K, TAI YT, LIN BK et ell.: Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with 131 integrin- and phosphatidylinositol 3-kinase-dependent PKCa activation. j. Biol. Chem. (2002) 277:7875–7881.
   Google Scholar
• YOSHIJI H, KURIYAMA S, WAYS DK et al.: Protein kinase C lies on the signaling pathway for vascular endothelial growth factor mediated tumor development and angiogenesis. Cancer Res. (1999) 59:4413–4418.
   PubMed Web of Science ®Google Scholar
• XIA P, AIELLO LP, ISHII H et al.: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. (1996) 98:2018–2026.
   PubMed Web of Science ®Google Scholar
• JOHNSON CL, LU D, HUANG J, BASU A: Regulation of p53 stabilization by DNA damage and protein kinase C. Mol Cancer Ther. (2002) 1:861–867.
   PubMed Web of Science ®Google Scholar
• ABBAS T, WHITE D, HUI Let al.: Inhibition of human p53 basal transcription by down-regulation of protein kinase 279 (2004) (9970–9977.)
   Google Scholar
• MAJUMDER PK, PANDEY P, SUN X et al.: Mitochondrial translocation of protein kinase C delta in phorbol ester-induced cytochrome c release and apoptosis. Biol . Chem. (2000) 275:21793–21796.
   Google Scholar
• BASU A: WOOLARD MD, JOHNSON CL: Involvement of protein kinase CO in DNA damage-induced apoptosis. Cell Death Dill: (2001) 8:899–908.
   PubMed Web of Science ®Google Scholar
• SUN X, WU F, DATTA R, KHARBANDA S, KUFE D: Interaction between protein kinase CO and the c-Abl tyrosine kinase in the cellular response to oxidative stress. j. Biol. Chem. (2000) 275:7470–7473.
   PubMedGoogle Scholar
• KOIVUNEN J, AALTONEN V, KOSKELA S et al.: Protein kinase Ca/f3 inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res. (2004) 64:5693–5701.
   PubMed Web of Science ®Google Scholar
• MATASSA AA, KALKOFEN RL, CARPENTER L, BIDEN TJ, REYLAND ME: Inhibition of PKCa induces a PKC8-dependent apoptotic program in salivary epithelial cells. Cell Death Differ. (2003) 10:269–277.
   PubMedGoogle Scholar
• LAHN M, SUNDELL K, MOORE S: Targeting protein kinase Ca (PKCa) in cancer with the phosphorothinate antisense oligonucleotide aprinocarsen. Ann. NY Acad. Sci. (2003) 1002:263–270.
   PubMedGoogle Scholar
• •Describes the design and development of oligonucleotides as specific inhibitors of PKCa and the clinical experiences with this drug.
   Google Scholar
• GRAFF JR, MCNULTY AIVI, HANNA KR et al.: Protein kinase CBI regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J. Biol. Chem. (2004) 279:45556–45563.
   PubMedGoogle Scholar
• CHEN L, HAHN H, WU G: Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc. Natl. Acad. Sci. USA (2001) 98:11114–11119.
   PubMed Web of Science ®Google Scholar
• O'NEILL MJ, CLEMENS JA: Rodent models of focal cerebral ischemia. In: Current Protocols in Neuroscience. Crawley JN, Gerfen CR, Rogawski MA et al. (Eds), John Wiley and Sons, NY, USA (2000):9.6.1–9.6.32.
   Google Scholar
• ARONOWSKI J, LABICHE LA: 2003 Perspectives on reperfusion-induced damage in rodent models of experimental focal ischemia and role of y-protein kinase C. ILAR J. (2003) 44:105–109.
   Google Scholar
• ARONOWSKI J, GROTTA JC, STRONG R: Interplay between they isoform of PKC and calcineurin in regulation of vulnerability to focal cerebral ischemia. J. Cereb. Blod Flow Metab. (2000) 20:343–349.
   PubMedGoogle Scholar
• AKITA: Protein kinase Cc (PKCc): its unique structure and function. J. Biochem. (2002) 132:847–852.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG SC: Protein kinase activation and myocardial ischemia/ reperfusion injury. Cardiovasc. Res. (2004) 61:427–436.
   PubMed Web of Science ®Google Scholar
• MURRIEL CL, MOCHLY-ROSEN D: Opposing roles of delta and epsilon PKC in cardiac ischemia and reperfusion: targeting the apoptotic machinery. Arch. Biochem. Biophys. (2003) 420:246–254.
   PubMed Web of Science ®Google Scholar
• LANGE-ASSCHENFELDT C, RAVAL AP, DAVE KR: Epsilon protein kinase C mediated ischemic tolerance requires activation of the extracellular regulated kinase pathway in the organotypic hippocampal slice. J. Cereb. Blood Flow Metab. (2004) 24:636–645.
   PubMedGoogle Scholar
• RAVAL AP, DAVE KR, MOCHLY -ROSEN D: Epsilon PKC is required for the induction of tolerance by ischemic and NMDA-mediated preconditioning in the organotypic hippocampal slice. J. Neurosci. (2003) 23:384–391.
   PubMed Web of Science ®Google Scholar
• BRODIE C, BLUMBERG PM: Regulation of cell apoptosis by protein kinase C 8. Apoptosis (2003) 8:19–27.
   PubMed Web of Science ®Google Scholar
• AMOS S, MARTIN PM, POLAR GA, PARSONS SJ, HUSSAINI IM: Phorbol 12-myristate 13-acetate induces epidermal growth factor receptor transactivation via protein kinase C8/c-Src pathways in glioblastoma cells. J. Biol. Chem. (2005) 280:7729.
   PubMedGoogle Scholar
• ANANTHARAM V, KITAZAWA M, WAGNER J, ALE: Caspase-3-dependent proteolytic cleavage of protein kinase Co is essential for oxidative stress-mediated dopaminergic cell death after exposure to methylcyclopentadienyl manganese tricarbonyl. j Neurosci. (2002) 22(1738–1751.)
   PubMed Web of Science ®Google Scholar
• MURRIEL CL, CHURCHILL E, INAGAKI K, ALE: Protein kinase CO activation induces apoptosis in response to cardiac ischemia and reperfusion damage: a mechanism involving BAD and the mitochondria. J. Biol. Chem. (2004) 279:47985–47991.
   PubMed Web of Science ®Google Scholar
• CHOU WH, CHOI DS, ZHANG H, AL E: Neutrophil protein kinase CO as a mediator of stroke-reperfusion injury. Clin. Invest. (2004) 114:49–56.
   Google Scholar
• BRIGHT R, RAVAL AP, DEMBNER JM, AL E: Protein kinase CO mediates cerebral reperfusion injury in vivo. J. Neurosci. (2004) 24:6880–6888.
   PubMed Web of Science ®Google Scholar
• HUDA R, VERGARA LA, SOLANKI DR, ALE: Selective activation of protein kinase CO in human neutrophils following ischemia reperfitsion of skeletal muscle. Shock (2004) 21:500–504.
   PubMedGoogle Scholar
• MIETTINEN S, ROIVAINEN R, KEINANEN R, ALE: Specific induction of protein kinase CO subspecies after transient middle cerebral artery occlusion in the rat brain: inhibition by MK-801.1 Neurosci. (1996) 16:6236–6245.
   Google Scholar
• AIELLO LP, HATA Y: Molecular mechanisms of growth factor action in diabetic retinopathy. Curr. Opin. Endocrinol Diabetes (1999) 6:146–156.
   Google Scholar
• SUZUMA K, TAKAHARA N, SUZUMA I et al.: Characterization of protein kinase CB isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc. Natl Acad. Sci. USA (2002) 99:721–726.
   PubMed Web of Science ®Google Scholar
• KOYA D, KING GL: Protein kinase C activation and the development of diabetic complications. Diabetes (1998) 47:859–866.
   PubMed Web of Science ®Google Scholar
• ISHII H, JIROUSEK MR, KOYA D et aL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKCB inhibitor. Science (1996) 272:728–731.
   PubMed Web of Science ®Google Scholar
• NAGPALA P, MALIK AB, VOUNG PT, LUM H: Protein kinase C01 overexpression augments phorbol ester-induced increase endothelial permeability. J. Cell Physiol (1996) 166:249–255.
   PubMed Web of Science ®Google Scholar
• DANIS RP, BINGAMAN DP, JIROUSEK M, YANG Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCB inhibition with LY333531. Invest. Opthalmol Vis. Sci. (1998) 39:171–179.
   PubMed Web of Science ®Google Scholar
• AIELLO LP, DAVIS MD, MILTON RC et al.: Initial results of the protein kinase CB inhibitor Diabetic Macular Edema Study (PKC-DMES). Diabetologia (2003) 46:A42.
   Google Scholar
• MILTON RC, AIELLO LP, DAVIS MD et al.: Initial results of the protein kinase CB inhibitor Diabetic Retinopathy Study (PKC-DRS). Diabetologia (2003) 46\(Supp1.2):A42.
   Google Scholar
• JOHNSON JE, GIORGIONE J, NEWTON AC: The Cl and C2 domains of protein kinase C are independent membrane targeting modules, with specificity for phosphatidylserine conferred by the Cl domain. Biochemistry (2000) 39:11360–11369.
   PubMed Web of Science ®Google Scholar
• KERANEN LM, NEWTON AC: Ca2* differentially regulates conventional protein kinase C's membrane interaction and activation. J. Biol. Chem. (1997) 272:25959–25967.
   PubMed Web of Science ®Google Scholar
• NISHIZUKA Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature (1988) 334:661–665.
   PubMed Web of Science ®Google Scholar
• ONO Y, FUJII T, IGARASHI K et ed: Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like sequence. Proc. Natl. Acad. Sci. USA (1989) 86:4868–4871.
   PubMed Web of Science ®Google Scholar
• HUWILER A, FABBRO D, PFEILSCHIFTER J: Selective ceramide binding to protein kinase Ca and 8 isoenzymes in renal mesangial cells. Biochemistry (1998) 37:14556–14562.
   PubMedGoogle Scholar
• RIZK AM, HAMMOUDA FM, ISMAIL SE, EL-MISSIRY MM, EVANS FJ: Irritant resiniferonol derivatives from Egyptian Thymelaea hirsuta L. Experientia (1984) 40:808–809.
   Google Scholar
• KOZIKOWSKI AP, WANG S, MAD et aL: Modeling, chemistry, and biology of the benzolactam analogues of indolactam V (ILV). 2. Identification of the binding site of the benzolactams in the CRD2 activator-binding domain of PKG8 and discovery of an ILV analogue of improved isozyme selectivity. J. Med. Chem. (1997) 40:1316–1326.
   Google Scholar
• •Design of new molecule benzolactams on the basis of binding profile of DAG and phorbol esters to PKC8 is described.
   Google Scholar
• KOZIKOWSKI AP, NOWAK I, PETUKHOV PA et al.: New amide-bearing benzolactam-based protein kinase C modulators induce enhanced secretion of the amyloid precursor protein metabolite sAPP. J. Med. Chem. (2003) 46:364–373.
   PubMed Web of Science ®Google Scholar
• SRIDHAR J, WEI Z-L, NOWAK I et al.: New bivalent PKC ligands linked by a carbon spacer: enhancement in binding affinity. J. Med. Chem. (2003) 46:4196–4204.
   PubMedGoogle Scholar
• WAY KJ, CHOU E, KING GL: Identification of PKC-isoform specific biological actions using pharmacological approaches. Trends Pharm. Sci. (2000) 21:181–187.
   PubMed Web of Science ®Google Scholar
• BUDWORTH J, DAVIES R, MALKHANDI J et al.: Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF7/Adr cells. Br. J. Cancer (1996) 73:1063–1068.
   PubMed Web of Science ®Google Scholar
• JONES CB, CLEMENTS MK, WASI S, DAOUD SS: Enhancement of camptothecin-induced cytotoxicity with UCNO1 in breast cancer cells: abrogation of S/G2 arrest. Cancer Chemother Pharm. (2000) 45:252–258.
   PubMedGoogle Scholar
• SUGIYAMA K, SCHIMUZU M, AKIYAMA T et al.: UCNO1 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G2 checkpoint abrogation. Int. J. Cancer (2000) 85:703–709.
   PubMedGoogle Scholar
• MARTINY-BARON G, KAZANIETZ MG, MISCHAK H et aL: Selective inhibition of protein kinase C isozymes by the indolocarbazole Go6976. J. Biol. Chem. (1993) 268:9194–9197.
   PubMed Web of Science ®Google Scholar
• WILKINSON SE, PARKER PJ, NIXON JS: Isoenzyme specificity of bisindolylmaleimides selective inhibitors of protein kinase C. Biochem. J. (1993) 294:335–337.
   PubMed Web of Science ®Google Scholar
• •Design and development of bisindolylmaleimide analogues is described and their specificity to PKC over other kinases as well as their selectivity profile for isozymes of PKC is given.
   Google Scholar
• MOHAMMED RM, WALL NR, DUTCHER JA, AL-KATIB AM: The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin. Cancer Res. (2000) 6:4950–4956.
   PubMedGoogle Scholar
• BIGNON E, PONS M, CRASTES DE et al.: Effect of triphenylacrylonitrile derivatives on oestradiol-receptor binding and on human breast cancer cell growth. J. Med. Chem. (1989) 32:2092–2103.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ GK, WARD D, SALTZ I: A Phase I study of the protein kinase C (PKC) specific inhibitor safingol (Sae alone and in combination with doxorubicin (Dox). Proc. Am. Soc. Clin. OncoL (1995) 14:479–489.
   Google Scholar
• MCKAY RA, MIRAGLIA LJ, CUMMINS LL et al.: Characterisation of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase Ca expression. J. Biol. Chem. (1999) 274:1715–1722.
   PubMed Web of Science ®Google Scholar
• ZHANG HC, DERIAN CK, MCCOMSEY DF et al.: Novel indolylindazolylmaleimides as inhibitors of protein kinase Cf3: synthesis, biological activity, and cardiovascular safety. J. Med. Chem. (2005) 48:1725–1728.
   PubMed Web of Science ®Google Scholar
• XU ZB, CHAUDHARY D, OLLAND S et al.: Catalytic domain crystal structure of protein kinase CO (PKCO). J. Biol. Chem. (2004) 279:50401–50409.
   PubMed Web of Science ®Google Scholar
• •Describes the crystal structure of PKC theta bound to staurosporine. Sequence comparison of the kinase domain of different isozymes of PKC is given.
   Google Scholar